WINSTON-SALEM, N.C., Nov. 15 /PRNewswire/ -- Targacept, Inc., a clinical- stage central nervous system-focused biopharmaceutical company, announced today that it presented research findings at the 35th annual meeting of the Society for Neuroscience.
(Logo: http://www.newscom.com/cgi-bin/prnh/20010517/CHTH002LOGO )
Targacept’s compounds are designed to act on a class of therapeutic targets called neuronal nicotinic acetylcholine receptors (NNRs) that are involved in regulating functions such as attention, memory and mood. Targacept researchers presented five posters summarizing recent preclinical work on compounds targeting either the alpha7 NNR or both the alpha7 and alpha4 beta2 NNRs. The alpha7 and alpha4 beta2 NNRs have been implicated in a number of CNS disorders. One of the Targacept posters described the results of several animal studies suggesting that a Targacept compound selective for the alpha7 NNR enhances cognition and reduces sensory gating deficits. Other posters described the results of studies on the development of novel mutant targets as tools in preclinical screening and the profile of several late preclinical compounds.
About Targacept
Targacept is a clinical-stage biopharmaceutical company engaged in the design, discovery and development of drugs to treat multiple diseases and disorders of the central nervous system by selectively targeting a class of receptors known as neuronal nicotinic acetylcholine receptors, or NNRs. Targacept is located in Winston-Salem, North Carolina.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20010517/CHTH002LOGOPRN Photo Desk, photodesk@prnewswire.comTargacept, Inc.
CONTACT: Alan Musso, VP and CFO of Targacept, Inc., +1-336-480-2186, oralan.musso@targacept.com; or Michelle Linn of Linnden Communications,+1-508-419-1555, or linnmich@comcast.net
Web site: http://www.targacept.com/
